Atopic Dermatitis

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

SCORE-AD Calculator & Atopic Dermatitis Assessment Tools for Healthcare Professionals. Access validated severity scales including SCORAD, EASI, vIGA-AD, DLQI, and POEM to evaluate disease severity, patient outcomes, and quality of life in one platform.

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

Citation: Geba et al. Journal of Allergy and Clinical Immunology 2025;Vol.151: 756-766

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.